Scarica l'app Stockscreener
0.7513
7.33%
0.0513
Dopo l'orario di chiusura:
.73
-0.0213
-2.84%
Precedente Chiudi:
$0.70
Aprire:
$0.6947
Volume 24 ore:
371.42K
Relative Volume:
0.34
Capitalizzazione di mercato:
$1.60M
Reddito:
$4.70M
Utile/perdita netta:
$-4.99M
Rapporto P/E:
-0.117
EPS:
-6.42
Flusso di cassa netto:
$-5.29M
1 W Prestazione:
+22.52%
1M Prestazione:
-37.39%
6M Prestazione:
-70.88%
1 anno Prestazione:
-64.89%
Intervallo 1D:
$0.6816
$0.77
Intervallo di 1 settimana:
$0.61
$0.77
Portata 52W:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Nome
Salarius Pharmaceuticals Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Confronta SLRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.7513 | 1.49M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Borsa (SLRX) Ultime notizie
Is Salarius Pharmaceuticals Inc. a good long term investmentRapid market gains - PrintWeekIndia
What analysts say about Salarius Pharmaceuticals Inc. stockLightning-fast capital gains - Autocar Professional
What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Salarius Pharmaceuticals Inc. Stock Analysis and ForecastRobust financial gains - jammulinksnews.com
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com Nigeria
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World
How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser
Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser
Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN
Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener
Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative
SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire
Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan
Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire
Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire
Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan
Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria
Salarius Pharmaceuticals Approves Reverse Stock Split - TipRanks
Why Is Salarius Pharmaceuticals Stock (SLRX) Up 110% Today? - The Globe and Mail
Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga
What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga
Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq
Salarius Pharmaceuticals Inc Azioni (SLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):